The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain

Abstract

BackgroundThe objective was to determine the economic burden, as well as the impact on HRQOL for people with HIV/AIDS in Spain in 2003.MethodsA cross-sectional study of 572 people with HIV were recruited from outpatient clinics in the Canary Islands, Spain. Demographic, health resources utilization, indirect costs and quality of life data were collected through medical records and questionnaires filled out by people with HIV. HRQOL was measured with two generic questionnaires: SF-36 and EQ-5D.ResultsIn 2003 annual costs of caring for patients with asymptomatic HIV, symptomatic HIV and AIDS were €10,351, €14,489 and €15,750, respectively. The HRQOL with the EQ-5D was 0.78. SF-36 summary results for physical and mental health were 48.30 and 38.80, respectively.ConclusionHIV/AIDS represent a high economic impact from society point of view. the structure of health care costs have changed due to these new drugs, increasing the weight of pharmaceutical treatment over total costs and decreasing the importance of inpatient care costs. In spite of the therapeutic improvements, labour losses/indirect costs still represent a high cost. Costs and HRQOL were strongly associated with severity. Although the latest drug developments have not yet been able to find the definitive cure, they have allowed an improvement in expectancy of life and in the HRQOL of the patients.

Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe

“…In our study, mean EQ-5D utility scores for FXS adult patients were lower than the mean values observed in the general population in both France and Hungary, where references are available [45,46]. In Italy, mean VAS score for adult FXS patients was lower than that measured in a sample representative of the Italian general population [47] and lower than the mean value for patients affected by HIV [48], similar to what was observed in Spain [49]. In Sweden, the mean utility score for adult FXS patients was lower than for patients suffering from a broad range of disorders, including diabetes, asthma, mental distress, hypertension, angina pectoris and neck/shoulder pain [50].…”

Social Economic Costs and Health‐Related Quality of Life in Patients With Systemic Sclerosis in Spain

“…We show that in 2011 the estimated annual cost per SSc patient was 荤21,041. Patients with SSc have higher mean annual costs compared to other chronic illnesses, such as human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) (荤13,823) (), stroke survivors during the first year after stroke (荤13,826) (), and ataxias (荤18,776) ().…”

“…Disease prevalence takes into account all existing cases during a given year and all health care resources used for prevention, treatment, and rehabilitation, plus other resources used (formal and informal care) or lost (labor productivity) within that year as a consequence of the illness considered. Prevalence‐based cost‐of‐illness analysis has the advantage of incorporating measurements of total annual health care expenditure, which is particularly relevant for chronic conditions such as SSc that require long‐term treatment (). In this context, a bottom‐up costing approach was used to estimate total and average annual costs ().…”

Economic Burden of HIV/AIDS Infection in Iran; a Modelling Approach

“…The direct cost was 20.4 US$, and the indirect cost was 9.7 US$ in 2017 (19). In Spain, the cost-of-illness for HIV infection in asymptomatic and symptomatic, and AIDS stages were 10,351 €, 14,489 € and 15,750 € respectively in 2003 (20).…”